Suppression of neuroinflammation in forebrain-specific Cdk5 conditional knockout mice by PPARγ agonist improves neuronal loss and early lethality

Journal of Neuroinflammation

Volumn 11, Issue , 2014, Pages

  Utreras, Elias ^a,d   Hamada, Ryusuke ^b   Prochazkova, Michaela ^a   Terse, Anita ^a   Takahashi, Satoru ^c   Ohshima, Toshio ^b   Kulkarni, Ashok B ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b WASEDA UNIVERSITY   (Japan)

^c ASAHIKAWA MEDICAL COLLEGE   (Japan)

^d UNIVERSITY OF CHILE   (Chile)

Author keywords

Cdk5; Cdk5 conditional knockout mice; Neuroinflammation; Pioglitazone; tPA

Indexed keywords

CYCLIN DEPENDENT KINASE 5; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BEHAVIOR DISORDER; CELL LOSS; CONTROLLED STUDY; FOREBRAIN; GLIOSIS; LETHALITY; LONGEVITY; MOUSE; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; CYCLIN-DEPENDENT KINASE 5; CYTOKINES; DISEASE MODELS, ANIMAL; ENCEPHALITIS; GENE EXPRESSION REGULATION; GLIOSIS; HYPOGLYCEMIC AGENTS; IMMUNOPRECIPITATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONS; PHOSPHOTRANSFERASES; PPAR GAMMA; PROSENCEPHALON; THIAZOLIDINEDIONES;

EID: 84893204721     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-11-28     Document Type: Article

References (46)

1. Dhavan R, Tsai LH. A decade of CDK5. Nat Rev Mol Cell Biol 2001, 2:749-759. 10.1038/35096019, 11584302.
2. Lew J, Huang QQ, Qi Z, Winkfein RJ, Aebersold R, Hunt T, Wang JH. A brain-specific activator of cyclin-dependent kinase 5. Nature 1994, 371:423-426. 10.1038/371423a0, 8090222.
3. Dhariwala FA, Rajadhyaksha MS. An unusual member of the Cdk family: Cdk5. Cell Mol Neurobiol 2008, 28:351-369. 10.1007/s10571-007-9242-1, 18183483.
4. Borquez DA, Olmos C, Alvarez S, Di Genova A, Maass A, Gonzalez-Billault C. Bioinformatic survey for new physiological substrates of Cyclin-dependent kinase 5. Genomics 2013, 101:221-228. 10.1016/j.ygeno.2013.01.003, 23384938.
5. Contreras-Vallejos E, Utreras E, Gonzalez-Billault C. Going out of the brain: non-nervous system physiological and pathological functions of Cdk5. Cell Signal 2012, 24:44-52. 10.1016/j.cellsig.2011.08.022, 21924349.
6. Utreras E, Futatsugi A, Pareek TK, Kulkarni AB. Molecular roles of Cdk5 in pain signaling. Drug Discov Today 2009, 6:105-111.
7. Ohshima T, Ward JM, Huh CG, Longenecker G, Veeranna, Pant HC, Brady RO, Martin LJ, Kulkarni AB. Targeted disruption of the Cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc Natl Acad Sci U S A 1996, 93:11173-11178. 10.1073/pnas.93.20.11173, 38303, 8855328.
8. Ohshima T, Hirasawa M, Tabata H, Mutoh T, Adachi T, Suzuki H, Saruta K, Iwasato T, Itohara S, Hashimoto M, et al. Cdk5 is required for multipolar-to-bipolar transition during radial neuronal migration and proper dendrite development of pyramidal neurons in the cerebral cortex. Development 2007, 134:2273-2282. 10.1242/dev.02854, 17507397.
9. Hirasawa M, Ohshima T, Takahashi S, Longenecker G, Honjo Y, Veeranna, Pant HC, Mikoshiba K, Brady RO, Kulkarni AB. Perinatal abrogation of Cdk5 expression in brain results in neuronal migration defects. Proc Natl Acad Sci U S A 2004, 101:6249-6254. 10.1073/pnas.0307322101, 395955, 15067135.
10. Takahashi S, Ohshima T, Hirasawa M, Pareek TK, Bugge TH, Morozov A, Fujieda K, Brady RO, Kulkarni AB. Conditional deletion of neuronal cyclin-dependent kinase 5 in developing forebrain results in microglial activation and neurodegeneration. Am J Pathol 2010, 176:320-329. 10.2353/ajpath.2010.081158, 2797893, 19948833.
11. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, O'Banion K, Klockgether T, Van Leuven F, Landreth GE. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 2005, 128:1442-1453. 10.1093/brain/awh452, 15817521.
12. Niino M, Iwabuchi K, Kikuchi S, Ato M, Morohashi T, Ogata A, Tashiro K, Onoe K. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma. J Neuroimmunol 2001, 116:40-48. 10.1016/S0165-5728(01)00285-5, 11311328.
13. Diab A, Deng C, Smith JD, Hussain RZ, Phanavanh B, Lovett-Racke AE, Drew PD, Racke MK. Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J Immunol 2002, 168:2508-2515.
14. Feinstein DL, Galea E, Gavrilyuk V, Brosnan CF, Whitacre CC, Dumitrescu-Ozimek L, Landreth GE, Pershadsingh HA, Weinberg G, Heneka MT. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol 2002, 51:694-702. 10.1002/ana.10206, 12112074.
15. Natarajan C, Bright JJ. Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. Genes Immun 2002, 3:59-70. 10.1038/sj.gene.6363832, 11960303.
16. Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 2002, 82:615-624. 10.1046/j.1471-4159.2002.00990.x, 12153485.
17. Dragatsis I, Zeitlin S. CaMKIIalpha-Cre transgene expression and recombination patterns in the mouse brain. Genesis 2000, 26:133-135. 10.1002/(SICI)1526-968X(200002)26:2<133::AID-GENE10>3.0.CO;2-V, 10686608.
18. Huang YY, Bach ME, Lipp HP, Zhuo M, Wolfer DP, Hawkins RD, Schoonjans L, Kandel ER, Godfraind JM, Mulligan R, et al. Mice lacking the gene encoding tissue-type plasminogen activator show a selective interference with late-phase long-term potentiation in both Schaffer collateral and mossy fiber pathways. Proc Natl Acad Sci U S A 1996, 93:8699-8704. 10.1073/pnas.93.16.8699, 38736, 8710934.
19. Andres M, Andre VM, Nguyen S, Salamon N, Cepeda C, Levine MS, Leite JP, Neder L, Vinters HV, Mathern GW. Human cortical dysplasia and epilepsy: an ontogenetic hypothesis based on volumetric MRI and NeuN neuronal density and size measurements. Cereb Cortex 2005, 15:194-210.
20. Utreras E, Keller J, Terse A, Prochazkova M, Iadarola MJ, Kulkarni AB. Transforming growth factor-beta1 regulates Cdk5 activity in primary sensory neurons. J Biol Chem 2012, 287:16917-16929. 10.1074/jbc.M111.329979, 3351291, 22451679.
21. Utreras E, Futatsugi A, Rudrabhatla P, Keller J, Iadarola MJ, Pant HC, Kulkarni AB. Tumor necrosis factor-alpha regulates cyclin-dependent kinase 5 activity during pain signaling through transcriptional activation of p35. J Biol Chem 2009, 284:2275-2284. 10.1074/jbc.M805052200, 2629110, 19049962.
22. Takahashi S, Ohshima T, Cho A, Sreenath T, Iadarola MJ, Pant HC, Kim Y, Nairn AC, Brady RO, Greengard P, Kulkarni AB. Increased activity of cyclin-dependent kinase 5 leads to attenuation of cocaine-mediated dopamine signaling. Proc Natl Acad Sci U S A 2005, 102:1737-1742. 10.1073/pnas.0409456102, 547862, 15665076.
23. Li BS, Zhang L, Takahashi S, Ma W, Jaffe H, Kulkarni AB, Pant HC. Cyclin-dependent kinase 5 prevents neuronal apoptosis by negative regulation of c-Jun N-terminal kinase 3. EMBO J 2002, 21:324-333. 10.1093/emboj/21.3.324, 125822, 11823425.
24. Li BS, Ma W, Jaffe H, Zheng Y, Takahashi S, Zhang L, Kulkarni AB, Pant HC. Cyclin-dependent kinase-5 is involved in neuregulin-dependent activation of phosphatidylinositol 3-kinase and Akt activity mediating neuronal survival. J Biol Chem 2003, 278:35702-35709. 10.1074/jbc.M302004200, 12824184.
25. O'Hare MJ, Kushwaha N, Zhang Y, Aleyasin H, Callaghan SM, Slack RS, Albert PR, Vincent I, Park DS. Differential roles of nuclear and cytoplasmic cyclin-dependent kinase 5 in apoptotic and excitotoxic neuronal death. J Neurosci 2005, 25:8954-8966. 10.1523/JNEUROSCI.2899-05.2005, 16192386.
26. Hisanaga S, Endo R. Regulation and role of cyclin-dependent kinase activity in neuronal survival and death. J Neurochem 2010, 115:1309-1321. 10.1111/j.1471-4159.2010.07050.x, 21044075.
27. Miyamoto Y, Yamauchi J, Chan JR, Okada A, Tomooka Y, Hisanaga S, Tanoue A. Cdk5 regulates differentiation of oligodendrocyte precursor cells through the direct phosphorylation of paxillin. J Cell Sci 2007, 120:4355-4366. 10.1242/jcs.018218, 18042622.
28. He X, Takahashi S, Suzuki H, Hashikawa T, Kulkarni AB, Mikoshiba K, Ohshima T. Hypomyelination phenotype caused by impaired differentiation of oligodendrocytes in Emx1-cre mediated Cdk5 conditional knockout mice. Neurochem Res 2011, 36:1293-1303. 10.1007/s11064-010-0391-0, 3431604, 21210220.
29. Bankston AN, Li W, Zhang H, Ku L, Liu G, Papa F, Zhao L, Bibb JA, Cambi F, Tiwari-Woodruff SK, Feng Y. p39, the primary activator for cyclin-dependent kinase 5 (Cdk5) in oligodendroglia, is essential for oligodendroglia differentiation and myelin repair. J Biol Chem 2013, 288:18047-18057. 10.1074/jbc.M113.453688, 23645679.
30. Yang Y, Wang H, Zhang J, Luo F, Herrup K, Bibb JA, Lu R, Miller RH. Cyclin dependent kinase 5 is required for the normal development of oligodendrocytes and myelin formation. Dev Biol 2013, 378:94-106. 10.1016/j.ydbio.2013.03.023, 23583582.
31. He Y, Li HL, Xie WY, Yang CZ, Yu AC, Wang Y. The presence of active Cdk5 associated with p35 in astrocytes and its important role in process elongation of scratched astrocyte. Glia 2007, 55:573-583. 10.1002/glia.20485, 17295212.
32. Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002, 2:748-759. 10.1038/nri912, 12360213.
33. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82-86. 10.1038/34184, 9422509.
34. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79-82. 10.1038/34178, 9422508.
35. Bernardo A, Minghetti L. PPAR-gamma agonists as regulators of microglial activation and brain inflammation. Curr Pharm Des 2006, 12:93-109. 10.2174/138161206780574579, 16454728.
36. Randy LH, Guoying B. Agonism of peroxisome proliferator receptor-gamma may have therapeutic potential for neuroinflammation and Parkinson's disease. Curr Neuropharmacol 2007, 5:35-46. 10.2174/157015907780077123, 2435341, 18615152.
37. Shibata N, Yamamoto T, Hiroi A, Omi Y, Kato Y, Kobayashi M. Activation of STAT3 and inhibitory effects of pioglitazone on STAT3 activity in a mouse model of SOD1-mutated amyotrophic lateral sclerosis. Neuropathology 2010, 30:353-360.
38. Yamanaka M, Ishikawa T, Griep A, Axt D, Kummer MP, Heneka MT. PPARgamma/RXRalpha-induced and CD36-mediated microglial amyloid-beta phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J Neurosci 2012, 32:17321-17331. 10.1523/JNEUROSCI.1569-12.2012, 23197723.
39. Cho DH, Lee EJ, Kwon KJ, Shin CY, Song KH, Park JH, Jo I, Han SH. Troglitazone, a thiazolidinedione, decreases tau phosphorylation through the inhibition of cyclin-dependent kinase 5 activity in SH-SY5Y neuroblastoma cells and primary neurons. J Neurochem 2013, 126:685-695. 10.1111/jnc.12264, 23581463.
40. Utreras E, Maccioni R, Gonzalez-Billault C. Cyclin-dependent kinase 5 activator p35 over-expression and amyloid beta synergism increase apoptosis in cultured neuronal cells. Neuroscience 2009, 161:978-987. 10.1016/j.neuroscience.2009.04.002, 19362124.
41. Shukla V, Skuntz S, Pant HC. Deregulated Cdk5 activity is involved in inducing Alzheimer's disease. Arch Med Res 2012, 43:655-662. 10.1016/j.arcmed.2012.10.015, 3532552, 23142263.
42. Su SC, Tsai LH. Cyclin-dependent kinases in brain development and disease. Annu Rev Cell Dev Biol 2011, 27:465-491. 10.1146/annurev-cellbio-092910-154023, 21740229.
43. Siao CJ, Tsirka SE. Tissue plasminogen activator mediates microglial activation via its finger domain through annexin II. J Neurosci 2002, 22:3352-3358.
44. Medina MG, Ledesma MD, Dominguez JE, Medina M, Zafra D, Alameda F, Dotti CG, Navarro P. Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1/2 activation. EMBO J 2005, 24:1706-1716. 10.1038/sj.emboj.7600650, 1142582, 15861134.
45. Pineda D, Ampurdanes C, Medina MG, Serratosa J, Tusell JM, Saura J, Planas AM, Navarro P. Tissue plasminogen activator induces microglial inflammation via a noncatalytic molecular mechanism involving activation of mitogen-activated protein kinases and Akt signaling pathways and AnnexinA2 and Galectin-1 receptors. Glia 2012, 60:526-540. 10.1002/glia.22284, 22162045.
46. Berta T, Liu YC, Xu ZZ, Ji RR. Tissue plasminogen activator contributes to morphine tolerance and induces mechanical allodynia via astrocytic IL-1beta and ERK signaling in the spinal cord of mice. Neuroscience 2013, 247:376-385.